Retatrutide

Retatrutide is a first-in-class triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, representing the next evolution beyond dual agonists like tirzepatide. This triple-agonist approach adds glucagon receptor activation to the incretin effects, potentially enhancing energy expenditure through hepatic and adipose tissue mechanisms.

The compound is engineered with balanced activity across all three receptors, though with predominant GIP agonism, followed by GLP-1 and glucagon activity. The C20 fatty acid modification enables albumin binding for extended half-life, supporting once-weekly administration in research settings.

Preclinical and clinical research has shown retatrutide produces the most substantial body weight reductions observed in metabolic peptide trials, with phase 2 data demonstrating mean weight loss exceeding 24% at higher doses. The glucagon component appears to contribute additional thermogenic effects and hepatic fat mobilization beyond what dual agonists achieve.

Retatrutide is being actively investigated for metabolic dysfunction-associated steatohepatitis (MASH), where its combined effects on appetite, insulin sensitivity, and direct hepatic glucagon action may provide comprehensive metabolic correction. Early research suggests potential for liver fat reduction exceeding 80% in responders.